




RealRate

PHARMACEUTICAL 2020

Syndax Pharmaceuticals Inc
Rank 250 of 363

Syndax



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 167%, being 71% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	62,331
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,368
Liabilities, Non-Current	13,557
Other Assets	913
Other Compr. Net Income	25
Other Expenses	0
Other Liabilities	0
Other Net Income	1,492
Other Revenues	1,517
Property and Equipment	281
Research and Development	42,994
Selling, General and Administrative Expense	16,062

Output Variable	Value in 1000 USD
Assets	63,525
Liabilities	31,925
Expenses	59,056
Revenues	1,517
Stockholders Equity	31,600
Net Income	-56,047
Comprehensive Net Income	-56,034
BaseVar	78,770
ECR before LimitedLiability	27%
Economic Capital Ratio	167%